# ajanta pharma limited

Regd.Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67

*Stand Alone Financial Results for the quarter ended 30th September, 2011*

₹ in Lacs

| Particulars | 3 months ended | | 6 months ended | | Year Ended |
|---|---|---|---|---|---|
| | 30/09/2011 | 30/09/2010 | 30/09/2011 | 30/09/2010 | 31/03/2011 |
| | Unaudited | | Unaudited | | Audited |
| 1. Net Sales/Income from Operations | **13,512.91** | **11,250.62** | **26,243.68** | **21,079.29** | **45,714.56** |
| 2. Expenditure | | | | | |
| a. (Increase)/decrease in stock in trade and work in progress | (1,008.78) | (373.13) | (1,352.41) | (1,308.01) | 537.37 |
| b. Consumption of raw & packing materials | 4,825.22 | 3,828.37 | 8,896.89 | 7,460.88 | 14,319.53 |
| c. Purchase of traded goods | 480.22 | 657.59 | 927.60 | 1,120.72 | 2,396.01 |
| d. Employees cost | 1,785.95 | 1,382.70 | 3,594.98 | 2,720.90 | 5,909.93 |
| e. Depreciation | 762.67 | 589.94 | 1,426.97 | 1,102.08 | 2,378.80 |
| f. Research & Development Expenses | 951.89 | 483.76 | 1,947.73 | 1,016.13 | 2,488.37 |
| g. Other expenditure | 4,156.37 | 3,179.56 | 7,778.68 | 6,191.19 | 11,108.47 |
| h. Total | **11,953.54** | **9,748.79** | **23,220.44** | **18,303.89** | **39,138.48** |
| 3. Profit from Operations before Other Income, Interest & Exceptional Items | **1,559.37** | **1,501.83** | **3,023.24** | **2,775.40** | **6,576.08** |
| 4. Other Income | 24.16 | 36.00 | 201.31 | 56.52 | 164.96 |
| 5. Profit before Interest & Exceptional items | **1,583.53** | **1,537.83** | **3,224.55** | **2,831.92** | **6,741.04** |
| 6. Interest | 337.16 | 435.22 | 622.11 | 870.33 | 1,565.82 |
| 7. Profit after Interest but before Exceptional Items | **1,246.37** | **1,102.61** | **2,602.44** | **1,961.59** | **5,175.22** |
| 8. Exceptional items | - | - | - | - | - |
| 9. Profit from Ordinary Activities before tax | **1,246.37** | **1,102.61** | **2,602.44** | **1,961.59** | **5,175.22** |
| 10.Tax Expense | 61.00 | 97.45 | 164.00 | 258.55 | 530.68 |
| 11. Net Profit from Ordinary Activities after tax | **1,185.37** | **1,005.16** | **2,438.44** | **1,703.04** | **4,644.54** |
| 12. Extraordinary items (net of tax expense) | - | - | - | - | - |
| 13. Net Profit for the period | **1,185.37** | **1,005.16** | **2,438.44** | **1,703.04** | **4,644.54** |
| 14. Paid-up Equity Share Capital (Face value of ₹10/- each) | 1,179.61 | 1,179.61 | 1,179.61 | 1,179.61 | 1,179.61 |
| 15. Reserve excluding Revaluation Reserve | NA | NA | NA | NA | 20,375.21 |
| 16. Earnings Per Share (EPS) | | | | | |
| Basic and diluted (not annualised) - ₹ | 10.12 | 8.58 | 20.83 | 14.55 | 39.67 |
| 17. Public Shareholding | | | | | |
| - Number of shares | 38,84,879 | 38,84,879 | 38,84,879 | 38,84,879 | 38,84,879 |
| - Percentage of shareholding | 33.18% | 33.18% | 33.18% | 33.18% | 33.18% |
| 18. Promoters and promoter group shareholding | | | | | |
| a) Pledged/Encumbered | | | | | |
| - Number of shares | 2,00,000 | 2,00,000 | 2,00,000 | 2,00,000 | 2,00,000 |
| - Percentage of total promoter's holding | 2.56% | 2.56% | 2.56% | 2.56% | 2.56% |
| - Percentage of total share capital of company | 1.71% | 1.71% | 1.71% | 1.71% | 1.71% |
| b) Non-encumbered | | | | | |
| - Number of shares | 76,23,621 | 76,23,621 | 76,23,621 | 76,23,621 | 76,23,621 |
| - Percentage of total promoter's holding | 97.44% | 97.44% | 97.44% | 97.44% | 97.44% |
| - Percentage of total share capital of company | 65.11% | 65.11% | 65.11% | 65.11% | 65.11% |

| **Statement of Assets & Liabilities** | | | | |
|---|---|---|---|---|
| SHAREHOLDERS FUND | | | | |
| (a) Capital | | 1,179.61 | 1,179.61 | 1,179.61 |
| (b) Reserves and Surplus | | 22,813.65 | 18,114.12 | 20,375.21 |
| LOAN FUNDS | | 18,971.56 | 17,881.48 | 15,827.83 |
| DEFERRED TAX LIABILITY | | 1,256.09 | 838.09 | 1,092.09 |
| | Total | 44,220.91 | 38,013.30 | 38,474.74 |
| FIXED ASSETS | | 24,246.59 | 21,386.49 | 22,340.51 |
| INVESTMENTS | | 1,705.29 | 1,705.13 | 1,705.04 |
| CURRENT ASSETS, LOANS AND ADVANCES | | | | |
| (a) Inventories | | 14,513.51 | 10,560.28 | 9,611.98 |
| (b) Sundry Debtors | | 8,707.36 | 6,589.87 | 7,576.43 |
| (c) Cash and Bank balances | | 1,380.46 | 316.70 | 1,253.56 |
| (d) Loans and Advances | | 4,912.36 | 4,319.15 | 4,803.26 |
| | Sub Total | 29,513.69 | 21,786.00 | 23,245.23 |
| Less: Current Liabilities and Provisions | | | | |
| (a) Liabilities | | 10,927.74 | 6,580.05 | 7,729.14 |
| (b) Provisions | | 316.92 | 284.27 | 1,086.90 |
| | Sub Total | 11,244.66 | 6,864.32 | 8,816.04 |
| Net Current Assets | | 18,269.03 | 14,921.68 | 14,429.19 |
| | Total | 44,220.91 | 38,013.30 | 38,474.74 |

Notes :

1. Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 24th October, 2011.
2. Statutory Auditors have carried out Limited Review of the above results.
3. The company has only one segment of activity namely, Pharmaceuticals.
4. Investor's Complaints status - Opening - 0, Received - 4, Resolved - 4, Closing - 0.
5. Previous period's figures have been regrouped wherever necessary.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 24th October, 2011

AJANTA PHARMA LIMITED